Insightec, a global healthcare company dedicated to using acoustic energy to transform patient care, announced that it has been awarded the 2023 BioFlorida David J. Gury Company of the Year Award for distinguished achievement in focused ultrasound technology and contributions to Florida’s life sciences industry. The award was presented at BioFlorida’s 26th Annual Conference in Ponte Verdra Beach to an audience of statewide leaders in Florida’s life sciences industry.
“Insightec is proud to receive this distinguished honor and inspired to continue our commitment to improve the quality of life of Floridians and millions of others battling essential tremor and Parkinson’s Disease around the world,” said Maurice R. Ferré MD, Insightec CEO and Chairman of the Board. “Our team works diligently every day to unlock the full potential of focused ultrasound and we are excited for the value this technology brings to the life sciences community and the future of patient care.”
The David J. Gury Company of the Year Award, named for one of the founding directors of BioFlorida, honors a company that has significant company achievements with measurable results including financing deals, partnering agreements, research discoveries, grants, clinical trials, approvals, product development and commercialization milestones. Recipients must also be BioFlorida members who demonstrate a history of service to BioFlorida and its mission – to advance the life sciences industry in Florida.
Also Read : Paycom launches Everyday, ensuring compliant daily payrolls
Insightec has been a pioneer in focused ultrasound (FUS) technology for more than 25 years. The company’s Exablate Neuro platform focuses sound waves, safely guided by MRI, to provide tremor relief to patients with medication-refractory essential tremor and Parkinson’s disease. Affecting approximately 60 million people globally, essential tremor is the most common movement disorder in the world and is often misdiagnosed. Essential tremor commonly affects both sides of the body, and in December 2022, Insightec received FDA approval to allow appropriate patients to have their second side treated at least nine months after treatment of the first side. The technology also received a CE mark for second side treatment in European countries in 2023.
SOURCE: PRNewswire